RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025.
At the effective time of the reverse split, every eight issued and outstanding shares of the Company's common stock will automatically be combined into one issued and outstanding share of the Company's common stock without any change in the par value per share. Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. The reverse stock split will not affect the absolute number of the Company's authorized shares of common stock, which will remain at 500,000,000, but the total number of authorized shares of the Company's common stock available for future issuance will increase. In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding pre-funded warrants and stock options, and to the number of shares of common stock issuable under the Company's equity incentive plans.
The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 132.3 million to approximately 16.5 million.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'will' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, pre-funded warrant holders and option holders, the potential impact of the reverse stock split on the bid price of the Company's common stock, the expected number of shares of common stock to be issued and outstanding following the reverse stock split, and other statements that are not historical fact. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Dogs of the Dow: Why Amgen's (AMGN) Dividend Power Makes it a Standout Pick
Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A pharmacist filling a prescription for a complex drug developed by the company. Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies looking to stay ahead of rivals, especially as biosimilar competition grows. The company boasts a robust pipeline, with dozens of ongoing programs that could result in future drug approvals and expanded uses for existing treatments. Thanks to its strong track record of innovation, Amgen has performed well for years, and that momentum is expected to continue. Amgen Inc. (NASDAQ:AMGN) also reported strong earnings in the first quarter of 2025. The company posted revenue of $8.15 billion, marking a 9.4% increase year-over-year. It benefited from strong global demand for its products. Management voiced optimism about its long-term growth prospects, supported by the success of recent product launches and encouraging Phase 3 trial outcomes for multiple treatments. Amgen Inc. (NASDAQ:AMGN)'s cash flow makes it one of the most reliable dividend stocks. The company generated $1.0 billion in free cash flow during the quarter, doubling the figure from the same period a year earlier. Operating cash flow rose to $1.4 billion from $0.7 billion in the prior year. The company also returned $1.3 billion to shareholders in the form of dividends. Amgen Inc. (NASDAQ:AMGN) offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.11%, as of July 26. The company has raised its dividends every year since 2011, which places it among the best dogs of the Dow. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Better EV Stock: Alphabet vs. Tesla (Hint: Robotaxis Are the Key)
Key Points The future of the auto industry lies in electric vehicles and ridesharing in autonomous vehicles. After many years in service, Waymo still can't point to a timeline of profitability. Tesla also faces challenges with its robotaxi offering, but it's well positioned, provided it can demonstrate safety and efficacy. These 10 stocks could mint the next wave of millionaires › Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) isn't, strictly speaking, an electric vehicle (EV) company. However, its autonomous driving technology company, Waymo, is committed to only using EVs in its fleet. Funnily enough, it could be argued that Tesla (NASDAQ: TSLA) isn't really a pure EV company either. After all, most of its sky–high valuation is attributable to the potential of its robotaxis. However, the comparison of these two as EV companies is valid because the future of the auto industry is EVs, and ridesharing in autonomous vehicles will be a larger part of the industry in the future. But which company is better placed, and which is the better stock? Alphabet vs. Tesla It's entirely possible that Alphabet could decide to spin off Waymo, not least because it reportedly could be valued at more than $45 billion. Meanwhile, one of Tesla's biggest supporters, Cathie Wood's Ark Invest, ascribes 88% of Tesla's enterprise value (market cap plus net debt) to robotaxis in its investment case for the stock, producing an expected value of $2,600 for the stock in 2029. As I have previously discussed, the Ark targets should be taken with a pinch of salt, as its track record on Tesla hasn't been good. However, Ark's core argument is sound and points to Tesla being potentially a far more valuable stock than Waymo ever will be. Pathways to profitability The core argument is that Tesla's business model is scalable to profitability while Waymo's is far less so. The issue of Waymo's profitability arose in a recent CNBC interview with Waymo co-CEO Tekedra Mawakana, where she was asked whether Waymo is profitable. She replied, "We're proving out that it can be a profitable business." When asked when Waymo would be profitable, she replied, "not clear." It's also not clear if Alphabet/Waymo doesn't have an internal forecast for when it will hit profitability, or if Mawakana preferred not to divulge what the company considers an uncertain forecast. However, it's inconceivable that Alphabet is not internally crunching the numbers on this, and if it does decide to spin off Waymo, it's a question that needs to be answered. The point here is that a business that can't be profitable isn't worth anything, let alone $45 billion, so at some point, its management is going to have to set some timelines. Tesla and timelines Whereas investors need to hear more about timelines from Waymo, whose public self-driving ride-hailing service was launched in 2018, there's probably a need for fewer declared timelines from Tesla, or, rather, a need for more accurate ones. For example, in 2019, CEO Elon Musk famously told investors to expect a million self-driving vehicles on the road by mid-2020. In April 2022, he also stated that Tesla aspired to reach volume production of a dedicated robotaxi (Cybercab) in 2024 -- a timeline that has now been pushed back to 2026. These timeline estimates matter because plugging overly optimistic assumptions from them into valuation models can produce dramatically erroneous conclusions. Why Tesla is better positioned With all that said, Tesla has clear advantages over Waymo, provided it can demonstrate safety and reliability and achieve regulatory approvals. Its advantages include: Lower vehicle costs, with Musk aiming for a $30,000 price tag for a dedicated robotaxi, the Cybercab. Meanwhile, Wall Street analysts estimate Waymo's current vehicles cost more than $120,000. In addition, Tesla manufactures its own cars (Waymo does not), and existing Teslas can be converted into robotaxis using Tesla's as-yet-unreleased-to-the-public unsupervised full self-driving (FSD) software, giving Tesla a significant advantage in scaling the robotaxi business. Tesla's use of camera-centric technology is inherently less expensive than Waymo's combination of cameras, light detection and ranging (Lidar) lasers, and high-definition maps. Every Tesla car (robotaxi or not) on the road is effectively a data gatherer, with the data used to improve the AI that powers its AI models. As such, even though Waymo was first, Tesla has significantly more data than Waymo. Which is the better EV stock? Waymo may become profitable in the future, particularly if Lidar costs continue to drop. However, it's challenging to think that it will be a strong competitor to Tesla, provided Musk's company can master safe, unsupervised FSD using a camera-centric approach. That's a big "if" at this stage, but it becomes a smaller "if" as time goes by and Tesla expands its nascent robotaxi offering across new geographies. Tesla's next robotaxi launch is expected to be in Phoenix, as it plans to continue slowly building its robotaxi business. I think Tesla is the better EV stock when comparing Tesla and Alphabet. Should you buy stock in Tesla right now? The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and Tesla. The Motley Fool has a disclosure policy. Better EV Stock: Alphabet vs. Tesla (Hint: Robotaxis Are the Key) was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Analyst sounds alarm on S&P 500 for August
Analyst sounds alarm on S&P 500 for August originally appeared on TheStreet. The stock market is on track to deliver another solid month of returns following its nearly 20% drop this spring. In July, the S&P 500 has returned 3% and the technology-heavy Nasdaq has rallied 3.6% so far, bringing the total returns for those indexes since April 9, when President Trump paused many tariffs, to 28% and 38% through July pretty impressive, especially since the S&P 500's annual return has been about 11.6% over the past 50 years. It remains to be seen if the S&P 500 can continue climbing in August to notch a fifth consecutive month of gains. The current rally may be getting a bit long in the tooth, given valuations have arguably stretched and some sentiment measures appear frothy. Long-time market analyst Jeffrey Hirsch, who is behind the closely watched Stock Trader's Almanac, also points out that August isn't necessarily kind to stocks. Stock market seasonal tailwinds ease in August Stocks move up and down for many reasons, including economic changes and revenue and earnings growth prospects. However, there's also a tendency for stocks to perform well in some months and poorly in others, something that the Stock Market Almanac has been tracking since Jeff Hirsh's father, Yale Hirsch, founded it in 1967. The Almanac is a treasure trove of historical probabilities, providing insight into historical index and sector performance Hirsh is credited with identifying the popular Santa Claus Rally, which holds that stocks tend to rise in the final five trading days of a year and the first two trading days of the following year, and the January Barometer, which suggests upside in January will lead to gains for the full year. One of the almanac's most closely considered trends is monthly average returns, and while stocks are historically solid performers in July, the backdrop isn't nearly as friendly in August. "August is the worst month in post-election years for DJIA and Russell 1000, 2nd worst for S&P 500, NASDAQ and Russell 2000," wrote Jeff Hirsch on X. Looking back to 1950, major market indexes have posted negative returns in August, making August one of the worst months of the year for stock market returns. "Average declines in post-election year Augusts range from –0.5% to –1.5%. Each index has seen more declining post-election year Augusts than positive," says Hirsch. According to the Stock Trader's Almanac data, here are the average returns in August for each major index since 1950, unless otherwise noted: Dow Jones Industrial Average: Down 1.5% S&P 500: Down 1.2%. NASDAQ (since 1971): Down 0.8%. Russell 1000 (since 1979): Down 1%. Russell 2000 (since 1979): Down 0.5%. The lackluster performance for these indexes in August ranks them either 11th or 12th worst out of all the months in the year. Dow Jones Industrial Average: 12th S&P 500: 11th NASDAQ: 11th Russell 1000: 12th Russell 2000: 11th. Valuation, the economy, and the Fed will impact what happens to stocks next The stock market has a lot going right for it recently. This spring's sell-off wrung out a lot of excess from stocks, setting the bar low enough so that anything shy of terrible news looks like a that to continue, however, we'll need things to continue to go just about perfectly, given the S&P 500's valuation is arguably stretched. The S&P 500's one-year forward price-to-earnings ratio, a common valuation measure that divides price by expected earnings, is 22.4, according to FactSet. That's about where it was in February, when stocks peaked before the tariff-driven sell-off. How the trade deals shake out with global partners like the EU will go a long way toward determining whether the economy will truly sidestep a recession. President Trump extended his pause on many reciprocal tariffs earlier in July, but set a hard stop date of August 1 for the pause. If trade deals fall short of expectations, rethinking how tariffs may impact inflation and the economy later this year could crimp the market rally. Similarly, most expect the Federal Reserve will cut interest rates in September. So far, there's been little economic data to suggest that's necessary. Consumer Price Index (CPI) Inflation, while sticky, was relatively timid in June at 2.7%. That's higher than the Fed wants, but still down from 3% in December. If unemployment picks up before September, the Fed may reduce rates by a quarter percentage point. The unemployment rate is 4.1%, which is about where it's trended since last summer. If the data remains status quo, with sticky inflation and a stable jobs market, the Fed may decide it can wait even longer before cutting. That may hurt stocks because lower rates fuel expansion and earnings growth. What does it all mean for investors? For most investors, month-to-month seasonality shouldn't impact their long-term investment plans. However, investors who consider themselves active day traders or position traders may want to pocket some of their recent profits to raise a little cash in case they get better buying opportunities if stocks swoon in August. After all, stocks rise over time but don't do it in a straight line. There are plenty of zigs and zags along the way. Analyst sounds alarm on S&P 500 for August first appeared on TheStreet on Jul 27, 2025 This story was originally reported by TheStreet on Jul 27, 2025, where it first appeared. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
